Royalty Table

Below are the disclosed royalties Ligand currently receives or is eligible to receive based on future drug approvals. 

Disclosed Licensed Royalties

Licensee Program Annual Royalty Structure
Amgen (1) Kyprolis 1.5% – Sales up to and including $250M
2.0% – Sales from $250M - $500M
2.5% – Sales in the range of $500M - $750M
3.0% – Sales greater than $750M
Acrotech/CASI (1) Evomela 20% on all sales
SAGE (1) Zulresso 3% on all sales
Pfizer (1) Viviant/Conbriza and Duavee 0.5% – Less than $400M
1.5% – Sales from $400M - $1.0B
2.5% – Sales greater than $1.0B
Palvella PTX-022 5.0% - 9.8%
Retrophin Sparsentan 9% on all sales
Viking TR Beta (VK2809 and VK0214) 3.5% - 7.5%
Sermonix Lasofoxifene 6.0% - 10.0%
CStone CS1001 Low single digit royalty on all sales
Gloria Various Low single digit royalty on all sales
Aldeyra Therapeutics Reproxalap Low single digit royalty on all sales
Arcus AB122 Low single digit royalty on all sales
Corvus Ciforadenant Mid-single digit to low-teen royalty
Dianomi Mineral Coated Microparticle 2.0% - 3.0%
Genagon OmniAb-Genagon 4.0% - 6.0%
Genekey PCSK-9 Low single digit royalty on all sales
GigaGen OmniAb-GigaGen Mid-single digit royalty
Kira OmniAb-Kira Low to mid-single digit royalty
KSQ Therapeutics OmniAb-KSQ Therapeutics Single digit royalty on all sales
MEI Pharma ME-143 and ME-344 Low single digit royalty on all sales
Melinta Baxdela 2.5% on all sales
iMetabolic OmniAb-iMetabolic <6%
Metavant RVT-1502 Low double digit to mid-teen royalty
Novan SB206 7.0% - 10.0%
Novartis KLM465 14.5% on all sales (6.5% in year one)
Nucorion Various 4.0% - 9.0%
Sedor CE-Budesonide and CE-Meloxicam 8.0% – Less than $25M
10.0% – Sales greater than $25M
Sedor CE-Fosphenytoin 11% on all sales
Seelos Various 4.0% - 10.0%
Takeda OmniAb-Takeda Low single digit royalty
TG Therapeutics IRAK4 6.0% - 9.5%
Verona Ensifentrine (RPL554) Low to mid-single digit royalty
Viking DGAT-1 3.0% - 7.0%
Viking FBPase Inhibitor (VK0612) 7.5% - 9.5%
Viking Oral EPO 4.5% - 8.5%
Viking SARM (VK5211) 7.25% - 9.25%
Xi'an Xintong MB07133 6% on all sales
Xi'an Xintong Pradefovir 9% on all sales
Zhilkang Hongyi 4-1BB Low single digit royalty on all sales
  1. Currently receiving royalty payments